Degenerative Disc Disease Pipeline Report 2023: Clinical trial analysis, Emerging Therapies and Key Companies by Delveinsight

DelveInsight's 'Degenerative Disc Disease Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline degenerative disc disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the degenerative disc disease pipeline domain.

To know more about Degenerative Disc Disease pipeline report, Click here @ https://www.delveinsight.com/report-store/degenerative-disc-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Degenerative Disc Disease Pipeline Report
• DelveInsight's degenerative disc disease pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for degenerative disc disease treatment.
• Key degenerative disc disease companies such as Spine BioPharma, Inc., Angitia Biopharmaceuticals, Mesoblast, Ltd., BioRestorative Therapies, DiscGenics, Inc., Biosplice Therapeutics, Notogen, AnGes, Inc., FibroGenesis, Genequine Biotherapeutics, Causeway Therapeutics, Boehringer Ingelheim, SpineOvations, BIOPHARM GmbH, Yuhan, Histogen Inc., and others are evaluating new drugs for degenerative disc disease to improve the treatment landscape.
• Promising degenerative disc disease pipeline therapies in various stages of development include SB-01, AGA111, Rexlemestrocel-L, BRTX-100, IDCT, Lorecivivint, AMG0103, CybroCell, GQ-401, CWT 002, DiscSeal, rhGDF-5, HST 004, and others.
• In January 2023, VySpine, that it has received 510(k) clearance from the FDA for its LumiVy NanoVy Ti Lumbar IBF System, which is indicated for intervertebral body fusion for use at either one level or two contiguous levels in the lumbar spine, from L2 to S1, for the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis.
• In January 2023, Notogen, Inc. announced that it had entered a worldwide research collaboration and license agreement with Boehringer Ingelheim to develop and commercialize a Notogen regenerative therapeutic that has the potential to become a first-in-class, disease modifying treatment for people living with degenerative disc disease (DDD).
• In November 2022, Spinal Stabilization Technologies (SST) announced the start of the LOPAIN2 clinical trial of the PerQdisc™ Nucleus Replacement Device (NRD). SST's PerQdisc Nucleus Replacement Device will be studied in patients with degenerative disc disease (DDD) of the lumbar spine, which causes severe back pain, in patients without stenosis or instability. The PerQdisc is used for surgical replacement of a single nucleus pulposus between spinal lumbar discs L1-S1 using an anterior or lateral transpsoas approach. Currently, there is no good surgical option for these patients. SST's PerQdisc NRD aims to treat discogenic low back pain while maintaining disc height and preserving range of motion.
• In February 2022, DiscGenics, Inc., announced the presentation of positive interim data from its ongoing Phase I/II clinical trial of IDCT (rebonuputemcel), an allogeneic injectable discogenic cell therapy for degenerative disc disease (DDD), at Spine Summit 2022. The primary efficacy endpoint of the study (n=60) was achieved, with statistically significant improvement in back pain observed in the high dose IDCT group. For these patients, low back pain scores improved >30% as measured on a 100mm Visual Analog Scale (VAS) at Weeks 12 (-54.53% [-69.46, -39.60], p=0.0056), 26 (-50.94% [-66.10, -35.78], p=0.0140), and 52 (-62.79% [-77.13, -48.46], p=0.0005).
• In January 2022, Mesoblast Limited announced 36-month follow-up results from the 404-patient Phase III trial of its allogeneic cell therapy rexlemestrocel-L (MPC-06-ID) in patients with chronic low back pain (CLBP) associated with degenerative disc disease (DDD).Results presented from this trial showed that: Durable reduction in pain through 36 months was greatest in the pre-specified population with CLBP of shorter duration than the study median of 68 months (n=194), suggesting that greatest benefits may be seen when the therapy is administered earlier in the disease process when there is active inflammation and before irreversible fibrosis of the intervertebral disc has occurred.

Request a sample and discover the recent advances in degenerative disc disease treatment drugs @ Degenerative Disc Disease Pipeline Report - https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The degenerative disc disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage degenerative disc disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the degenerative disc disease clinical trial landscape.

Degenerative Disc Disease Overview
The term "degenerative disc disease" (spondylosis) refers to the regular changes that occur in human spinal discs as they age. Normally, the discs act as shock absorbers for the human spine, allowing the body to flex, bend, and twist. This disease frequently causes various disorders, including lumbar spinal stenosis, spondylolisthesis, and retrospondylolisthesis. Approximately 90% of people will experience debilitating back pain at some point in their lives. The vast majority of cases are asymptomatic. The most common degenerative disk disease symptoms are neck pain and back pain.
The goal of degenerative disk disease treatment is to alleviate pain and prevent further damage. If other treatments fail, the doctor may suggest surgery. A discectomy is a procedure that removes the injured part of the disk. This relieves tension on the nerves. Sometimes, the doctor may remove the entire disk and replace it with an artificial one. If the patient has a severe problem, the doctor may fuse (permanently connect) the bones in the spine after the disk is removed.

Find out more about degenerative disc disease treatment drugs @ Drugs for Degenerative Disc Disease Treatment - https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Degenerative Disc Disease Therapeutics Assessment
The degenerative disc disease pipeline report proffers an integral view of degenerative disc disease emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Degenerative Disc Disease Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
• Therapeutics Assessment By Mechanism of Action: IL17A protein inhibitors, MAP-kinase-activated kinase 2 inhibitors, IL17F protein inhibitors, Janus kinase 1 inhibitors, Immunomodulators, Granulocyte macrophage colony stimulating factor antagonists
• Key Degenerative Disc Disease Companies: Spine BioPharma, Inc., Angitia Biopharmaceuticals, Mesoblast, Ltd., BioRestorative Therapies, DiscGenics, Inc., Biosplice Therapeutics, Notogen, AnGes, Inc., FibroGenesis, Genequine Biotherapeutics, Causeway Therapeutics, Boehringer Ingelheim, SpineOvations, BIOPHARM GmbH, Yuhan, Histogen Inc., and others.
• Key Degenerative Disc Disease Pipeline Therapies: SB-01, AGA111, Rexlemestrocel-L, BRTX-100, IDCT, Lorecivivint, AMG0103, CybroCell, GQ-401, CWT 002, DiscSeal, rhGDF-5, HST 004, and others.

Dive deep into rich insights for new drugs for degenerative disc disease treatment; visit @ Degenerative Disc Disease Medications - https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Degenerative Disc Disease Pipeline Report Introduction
2. Degenerative Disc Disease Pipeline Report Executive Summary
3. Degenerative Disc Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Degenerative Disc Disease Clinical Trial Therapeutics
6. Degenerative Disc Disease Pipeline: Late Stage Products (Pre-registration)
7. Degenerative Disc Disease Pipeline: Late Stage Products (Phase III)
7.1 Rexlemestrocel-L: Mesoblast, Ltd.
8. Degenerative Disc Disease Pipeline: Mid Stage Products (Phase II)
8.1. BRTX-100: BioRestorative Therapies
9. Degenerative Disc Disease Pipeline: Early Stage Products (Phase I)
10. Degenerative Disc Disease Pipeline Therapeutics Assessment
11. Inactive Products in the Degenerative Disc Disease Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Degenerative Disc Disease Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the degenerative disc disease pipeline therapeutics, reach out @ Degenerative Disc Disease Treatment Drugs - https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.